These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8490845)

  • 21. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
    Hartman AR; Grekowicz A; Lum BL; Carlson RW; Schurman C; Sikic BI; Shapiro R; Stockdale FE
    Breast Cancer Res Treat; 2003 Nov; 82(1):61-9. PubMed ID: 14672404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of paclitaxel with oral etoposide in advanced solid tumors.
    Perez EA; Coe T; Turrell C; Lau D; Campbell D; Gandara D
    Cancer J Sci Am; 1996; 2(5):286-90. PubMed ID: 9166546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA; Kelly K
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):11-5. PubMed ID: 9007114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose etoposide for refractory malignancies: a phase I study.
    Postmus PE; Mulder NH; Sleijfer DT; Meinesz AF; Vriesendorp R; de Vries EG
    Cancer Treat Rep; 1984 Dec; 68(12):1471-4. PubMed ID: 6509453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation.
    Oblon DJ; Paul SR; Oblon MB; Malik S
    Bone Marrow Transplant; 1997 Dec; 20(11):961-3. PubMed ID: 9422475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
    Viale PH
    Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion.
    Beyer J; Grabbe J; Lenz K; Weisbach V; Strohscheer I; Huhn D; Siegert W
    Bone Marrow Transplant; 1992 Dec; 10(6):491-4. PubMed ID: 1362685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
    Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
    Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer.
    Masuda N; Fukuoka M; Matsui K; Negoro S; Takada M; Sakai N; Ryu S; Takifuji N; Ito K; Kudoh S
    Cancer; 1990 Jun; 65(12):2635-40. PubMed ID: 1692757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.